Because COVID-19 is spreading more rapidly in the U.S., the drugmaker will likely be able to get the data it needs to prove its vaccine is safe and effective quicker, so it doesn’t need to enroll as many participants.
The drugmaker said its interim vaccine data could be available by the end of January if the vaccine is safe and effective, and an emergency use authorization application could be submitted in February, according to CNBC.
Moncef Slaoui, PhD, chief of Operation Warp Speed, the White House’s initiative to speed COVID-19 vaccine and drug development, indicated the results could come as soon as early January, with an emergency approval coming in late January, CNBC reported.
Johnson & Johnson’s vaccine requires just one dose, as opposed to two like Pfizer and Moderna’s candidates, so it could help significantly ramp up supply of COVID-19 vaccines if approved, CNBC reported.
More articles on pharmacy:
Novo Nordisk to end 340B discounts on drugs dispensed at community pharmacies
3 recent leadership changes at CVS
90-year-old British woman becomes first person vaccinated for COVID-19 outside of clinical trial
